Monthly Archives: April 2016

Change Happens: The Incredibly Rapid Pace of Change In Cancer Care

Change is a good thing, a necessary thing. At the same time, I have to ask how many realize how much change is happening so quickly in oncology and cancer care? And I wonder even more how we are going to separate change that is valuable from change that is simply, well, for the sake of change.

What brought about this moment of reflection was my attendance at a conference this past week sponsored by the American Cancer Society Cancer Action Network focused on the future of health care. The specific topic was “The Role of Technology in America’s Shifting Health Care Landscape.”

 After spending a day listening to discussions of change in cancer care—led primarily by emerging data analytics and health information technology—I was struck how the cancer landscape might be shifting quickly in ways that many of us don’t understand, and in fact can’t fathom. Putting the pieces of this puzzle together in a rational way in my opinion is beyond the capabilities of many of us, even those who have devoted our lives to understanding cancer.Continue reading →

Need To Balance Innovation, Benefits and Restraint When It Comes To The Rising The Costs Of Cancer Drugs

Cancer drugs—especially the new targeted and immunotherapies—are very, very expensive.

No doubt about that, and there is also no lack of effort trying to cast blame on who bears responsibility for those costs. There is even a recent article in the British Medical Journal that analyzes the size of the vials those drugs come in and suggests for some companies at least that may be a strategy to increase costs even further. What most experts can agree on is that this is a complicated problem for which there are no easy solutions.

I recently wrote a short commentary on the issue which appeared in Healio’s “HemOnc Today.” Although not exhaustive in terms of analyzing the issue, it does point out that we need to find a balance that continues to provide the incentive to innovate and bring new treatments to the care of cancer patients, while maintaining some degree of restraint given the reality that these costs simply cannot continue to increase without limit.… Continue reading →